{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:01Z","timestamp":1790616361588,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,8,22]],"date-time":"2014-08-22T00:00:00Z","timestamp":1408665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s10637-014-0151-0","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T01:52:14Z","timestamp":1408585934000},"page":"1246-1257","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"32","author":[{"given":"Nizar M.","family":"Tannir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Forero-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"de Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy C.","family":"Whiting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaina M.","family":"Gartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiteng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"151_CR1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.4049\/jimmunol.152.4.1756","volume":"152","author":"MR Bowman","year":"1994","unstructured":"Bowman MR, Crimmins MA, Yetz-Aldape J et al (1994) The cloning of CD70 and its identification as the ligand for CD27. J Immunol 152:1756\u201361","journal-title":"J Immunol"},{"key":"151_CR2","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4049\/jimmunol.174.2.710","volume":"174","author":"TN Bullock","year":"2005","unstructured":"Bullock TN, Yagita H (2005) Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol 174:710\u20137","journal-title":"J Immunol"},{"key":"151_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/0092-8674(93)90133-B","volume":"73","author":"RG Goodwin","year":"1993","unstructured":"Goodwin RG, Alderson MR, Smith CA et al (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73:447\u201356","journal-title":"Cell"},{"key":"151_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1046\/j.1365-2567.1997.00134.x","volume":"90","author":"SM Lens","year":"1997","unstructured":"Lens SM, Baars PA, Hooibrink B et al (1997) Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells. Immunology 90:38\u201345","journal-title":"Immunology"},{"key":"151_CR5","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1002\/eji.1830261223","volume":"26","author":"SM Lens","year":"1996","unstructured":"Lens SM, de Jong R, Hooibrink B et al (1996) Phenotype and function of human B cells expressing CD70 (CD27 ligand). Eur J Immunol 26:2964\u201371","journal-title":"Eur J Immunol"},{"key":"151_CR6","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1046\/j.1365-2249.1997.d01-942.x","volume":"107","author":"AM Orengo","year":"1997","unstructured":"Orengo AM, Cantoni C, Neglia F et al (1997) Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity. Clin Exp Immunol 107:608\u201313","journal-title":"Clin Exp Immunol"},{"key":"151_CR7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/0161-5890(95)00016-8","volume":"32","author":"MC Peitsch","year":"1995","unstructured":"Peitsch MC, Tschopp J (1995) Comparative molecular modelling of the Fas-ligand and other members of the TNF family. Mol Immunol 32:761\u201372","journal-title":"Mol Immunol"},{"key":"151_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1517\/14728222.12.3.341","volume":"12","author":"IS Grewal","year":"2008","unstructured":"Grewal IS (2008) CD70 as a therapeutic target in human malignancies. Expert Opin Ther Targets 12:341\u201351","journal-title":"Expert Opin Ther Targets"},{"key":"151_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0167-5699(94)90077-9","volume":"15","author":"RQ Hintzen","year":"1994","unstructured":"Hintzen RQ, de Jong R, Lens SM et al (1994) CD27: marker and mediator of T-cell activation? Immunol Today 15:307\u201311","journal-title":"Immunol Today"},{"key":"151_CR10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1006\/smim.1998.0154","volume":"10","author":"SM Lens","year":"1998","unstructured":"Lens SM, Tesselaar K, van Oers MH et al (1998) Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 10:491\u20139","journal-title":"Semin Immunol"},{"key":"151_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.coi.2005.04.004","volume":"17","author":"J Borst","year":"2005","unstructured":"Borst J, Hendriks J, Xiao Y (2005) CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 17:275\u201381","journal-title":"Curr Opin Immunol"},{"key":"151_CR12","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1182\/blood-2007-03-082578","volume":"110","author":"ZZ Yang","year":"2007","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC et al (2007) CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4 + CD25 T cells. Blood 110:2537\u201344","journal-title":"Blood"},{"key":"151_CR13","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.ejca.2005.05.005","volume":"41","author":"J Diegmann","year":"2005","unstructured":"Diegmann J, Junker K, Gerstmayer B, Bosio A, Hindermann W, Rosenhahn J et al (2005) Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry. Eur J Cancer 41:1794\u2013801","journal-title":"Eur J Cancer"},{"key":"151_CR14","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-05-2883","volume":"66","author":"CL Law","year":"2006","unstructured":"Law CL, Gordon KA, Toki BE et al (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Can cer Res 66:2328\u201337","journal-title":"Can cer Res"},{"key":"151_CR15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1365-2141.1999.01573.x","volume":"106","author":"SM Lens","year":"1999","unstructured":"Lens SM, Drillenburg P, den Drijver BF et al (1999) Aberrant expression and reverse signalling of CD70 on malignant B cells. Br J Haematol 106:491\u2013503","journal-title":"Br J Haematol"},{"key":"151_CR16","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1158\/0008-5472.CAN-11-2791","volume":"72","author":"C Claus","year":"2012","unstructured":"Claus C, Riether C, Sch\u00fcrch C et al (2012) CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 72:3664\u201376","journal-title":"Cancer Res"},{"key":"151_CR17","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/1078-0432.CCR-08-0916","volume":"14","author":"E Oflazoglu","year":"2008","unstructured":"Oflazoglu E, Stone IJ, Gordon K et al (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14:6171\u201380","journal-title":"Clin Cancer Res"},{"key":"151_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1182\/blood-2006-07-034017","volume":"109","author":"JA McEarchern","year":"2007","unstructured":"McEarchern JA, Oflazoglu E, Francisco L et al (2007) Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 109:1185\u201392","journal-title":"Blood"},{"key":"151_CR19","doi-asserted-by":"publisher","first-page":"7763","DOI":"10.1158\/1078-0432.CCR-08-0493","volume":"14","author":"JA McEarchern","year":"2008","unstructured":"McEarchern JA, Smith LM, McDonagh CF et al (2008) Preclinical characterization of SGN-70, a humanized antibody directed against CD70. Clin Cancer Res 14:7763\u201372","journal-title":"Clin Cancer Res"},{"key":"151_CR20","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812\u201321","journal-title":"N Engl J Med"},{"key":"151_CR21","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.bjc.6605816","volume":"103","author":"MC Ryan","year":"2010","unstructured":"Ryan MC, Kostner H, Gordon KA et al (2010) Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody\u2013drug conjugate SGN-75. Br J Cancer 103:676\u201384","journal-title":"Br J Cancer"},{"key":"151_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u201347","journal-title":"Eur J Cancer"},{"key":"151_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u201386","journal-title":"J Clin Oncol"},{"key":"151_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3324\/haematol.11934","volume":"93","author":"AW Hauswirth","year":"2008","unstructured":"Hauswirth AW, Skrabs C, Sch\u00fctzinger C et al (2008) Autoimmune thrombocytopenia in non-Hodgkin\u2019s lymphomas. Haematologica 93:447\u201350","journal-title":"Haematologica"},{"key":"151_CR25","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1200\/JCO.2011.39.4403","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Kim S, Romaguera J et al (2012) Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed\/refractory B-cell lymphoma. J Clin Oncol 30:2776\u201382","journal-title":"J Clin Oncol"},{"key":"151_CR26","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: results of a phase II study. J Clin Oncol 30:2190\u20136","journal-title":"J Clin Oncol"},{"key":"151_CR27","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30:2183\u20139","journal-title":"J Clin Oncol"},{"key":"151_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1124\/jpet.109.155549","volume":"330","author":"SC Alley","year":"2009","unstructured":"Alley SC, Zhang X, Okeley NM et al (2009) The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 330:932\u20138","journal-title":"J Pharmacol Exp Ther"},{"key":"151_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.immuni.2012.09.009","volume":"38","author":"JM Coquet","year":"2013","unstructured":"Coquet JM, Middendorp S, van der Horst G et al (2013) The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity. Immunity 38:53\u201365","journal-title":"Immunity"},{"key":"151_CR30","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1182\/blood-2007-04-084525","volume":"112","author":"AW Ho","year":"2008","unstructured":"Ho AW, Hatjiharissi E, Ciccarelli BT et al (2008) CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood 112:4683\u20139","journal-title":"Blood"},{"key":"151_CR31","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/bc400217g","volume":"24","author":"SC Jeffrey","year":"2013","unstructured":"Jeffrey SC, Burke PJ, Lyon RP et al (2013) A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 24:1256\u201363","journal-title":"Bioconjug Chem"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0151-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-014-0151-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0151-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-014-0151-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:56:26Z","timestamp":1678510586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-014-0151-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["151"],"URL":"https:\/\/doi.org\/10.1007\/s10637-014-0151-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]},"assertion":[{"value":"29 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}